Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vadastuximab talirine
- Development stage
- Discontinued
- Lead developer
- Skagen
- Modality
- Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vadastuximab talirine is an antibody-drug conjugate (ADC) developed for the treatment of acute myeloid leukemia (AML). It consists of a humanized monoclonal antibody targeting CD33—a transmembrane receptor expressed on cells of myeloid lineage—conjugated to a highly potent DNA-binding cytotoxic agent, pyrrolobenzodiazepine (PBD) dimer. The antibody binds to CD33-expressing cells and is internalized; within lysosomes, the linker is cleaved to release the PBD dimer. The released PBD crosslinks DNA in target cells, causing cell cycle arrest and apoptosis at very low concentrations. Vadastuximab talirine was developed by Seagen and underwent clinical trials for AML but its development was discontinued after phase III due to safety concerns[2][3][6][7].
- Other names
- vadastuximab talirineSGN-CD33ASGN-CD-33ASGN-CD 33A33A
02
Targets
DNACD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on vadastuximab talirine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vadastuximab talirine.